Cite

HARVARD Citation

    Stalder, A. et al. (n.d.). Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949. British journal of clinical pharmacology. pp. 476-486. [Online]. 
  
Back to record